{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-003816","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.616646+00:00","generated_at":"2026-06-27T04:37:05.457930+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cardiff Oncology reports Q4/FY2021 results; mCRC trial shows 34% ORR; Pfizer invests $15M","bullets":["Onvansertib+FOLFIRI/bevacizumab in KRAS-mutated mCRC: 34% (12/35) ORR at RP2D; mPFS 9.4 months vs ~4.5-5.7 months historical control.","Cash, equivalents, and short-term investments $141M as of Dec 31, 2021; Q4 operating expenses $9.6M (up from $6.6M in 2020).","Pfizer invested $15M via equity purchase of 2.4M shares at $6.22 (19% premium); Pfizer executive to join Scientific Advisory Board.","Appointed Tod Smeal as CSO (ex-Eli Lilly, Pfizer) and Charles Monahan as SVP Regulatory Affairs.","Full year 2021 net cash used in operating activities $23.0M vs $16.3M in 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-003816","json":"https://secwatch.observer/filing/0001628280-22-003816.json","markdown":"https://secwatch.observer/filing/0001628280-22-003816.md","text":"https://secwatch.observer/filing/0001628280-22-003816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022003816/0001628280-22-003816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022003816/crdf-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:37:05.457930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}